PharmTech Drug Digest 11.20
News|Articles|February 2, 2016

Catalent Expands Singapore Clinical Trials Hub

Catalent plans a $4.6 million investment to expand secondary packaging and storage in Asia.

Catalent Pharma Solutions announced on Feb. 2, 2016 an investment of $4.6 million to expand its Singapore clinical supply facility by building GMP space for secondary packaging. The investment will double the ambient storage space and quadruple cold storage capacity, the company reports.

Established in 1998, Catalent’s Singapore site provides clinical supply services including project and supply chain management, comparator sourcing, clinical label printing, secondary packaging, clinical storage, import/export management, importer of record service, and returns and destruction management services. It has served as a key regional hub for studies in Australia, Singapore, Korea, Hong Kong and other countries in Southeast Asia.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.